The overall goals of this laboratory are to develop novel targeted immunotherapies based on effectors of the immune system and to understand their mechanisms of action as well as the mechanisms of resistance to them. This includes antibodies, targeted nano-devices, engineered cells, and active specific agents such vaccines. An important goal is to take these new therapies into human clinical trials for testing. We developed a molecular nanogenerator that releases alpha particles inside cancer cells, now being tested in Phase II humans. Read full article in Science (Science, 2001) and a WT1 vaccine, also in late stage national trials (Blood, 2010.)
We have developed targeted alpha particle therapies, targeted beta emitters, oncogenic protein peptide vaccines, humanized antibodies, each of which reached human clinical trials; More recently we have discovered TCR mimic antibodies to intracellular proteins (Science Trans. Med., 2013), (Nature Biotech., 2015), as well as prototype targeted nano-machines (Nature Nano, 2013).
David A. Scheinberg, MD, PhD
Chair, Molecular Pharmacology Program, SKI; Director, Center for Experimental Therapeutics, MSK
Research FocusMolecular Pharmacology Program Chair David Scheinberg focuses on the discovery and development of novel, specific immunotherapeutic agents and targeted nanodevices for cancer therapy.
EducationMD, PhD, Johns Hopkins University School of Medicine
- Alidori S, Akhavein N, Thorek DL, Behling K, Romin Y, Queen D, Beattie BJ, Manova-Todorova K, Bergkvist M, Scheinberg DA, McDevitt MR. Targeted fibrillar nanocarbon RNAi treatment of acute kidney injury. Science Translational Medicine. 2016; 8(331):331ra39.[PMID: 27009268].